Weekly Analysts’ Ratings Changes for Johnson & Johnson (JNJ)

Johnson & Johnson (NYSE: JNJ) has recently received a number of price target changes and ratings updates:

• 3/19/2026 – Johnson & Johnson had its price target raised by Barclays PLC from $217.00 to $234.00. They now have an “equal weight” rating on the stock.
• 3/18/2026 – Johnson & Johnson was given a new $253.00 price target by Morgan Stanley.
• 3/18/2026 – Johnson & Johnson had its “overweight” rating reaffirmed by Morgan Stanley.
• 3/17/2026 – Johnson & Johnson had its price target raised by HSBC Holdings plc from $265.00 to $280.00. They now have a “buy” rating on the stock.
• 3/11/2026 – Johnson & Johnson had its price target raised by Citigroup Inc. from $250.00 to $274.00. They now have a “buy” rating on the stock.
• 3/5/2026 – Johnson & Johnson had its price target raised by JPMorgan Chase & Co. from $225.00 to $250.00. They now have a “neutral” rating on the stock.
• 3/2/2026 – Johnson & Johnson had its “neutral” rating reaffirmed by Bank of America Corporation.
• 2/19/2026 – Johnson & Johnson had its price target raised by Rothschild & Co Redburn from $180.00 to $210.00. They now have a “neutral” rating on the stock.
• 2/14/2026 – Johnson & Johnson was downgraded by Wall Street Zen from “buy” to “hold”.
• 2/3/2026 – Johnson & Johnson had its price target raised by Royal Bank Of Canada from $240.00 to $255.00. They now have an “outperform” rating on the stock.
• 1/30/2026 – Johnson & Johnson had its price target raised by HSBC Holdings plc from $240.00 to $265.00. They now have a “buy” rating on the stock.
• 1/29/2026 – Johnson & Johnson had its price target raised by Daiwa Securities Group Inc. from $203.00 to $237.00. They now have an “outperform” rating on the stock.
• 1/28/2026 – Johnson & Johnson had its “buy (b)” rating reaffirmed by Weiss Ratings.
• 1/28/2026 – Johnson & Johnson was given a new $262.00 price target by Morgan Stanley. They now have an “overweight” rating on the stock.
• 1/27/2026 – Johnson & Johnson was given a new $220.00 price target by Loop Capital.
• 1/25/2026 – Johnson & Johnson was upgraded by Wall Street Zen from “hold” to “buy”.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th were given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date of this dividend was Tuesday, February 24th. Johnson & Johnson’s payout ratio is 47.06%.

Insider Activity

In other news, EVP Timothy Schmid sold 1,322 shares of the stock in a transaction on Friday, February 20th. The shares were sold at an average price of $245.66, for a total value of $324,762.52. Following the completion of the sale, the executive vice president owned 25,447 shares of the company’s stock, valued at $6,251,310.02. This represents a 4.94% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Vanessa Broadhurst sold 6,197 shares of the firm’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the completion of the transaction, the executive vice president directly owned 23,003 shares in the company, valued at approximately $5,598,700.17. This represents a 21.22% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 30,142 shares of company stock valued at $7,360,528 over the last 90 days. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.